Stryker Co. (NYSE:SYK) Stock Holdings Increased by Scharf Investments LLC

Scharf Investments LLC lifted its holdings in Stryker Co. (NYSE:SYK) by 7.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,052 shares of the medical technology company’s stock after purchasing an additional 537 shares during the quarter. Scharf Investments LLC’s holdings in Stryker were worth $2,899,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Capital Planning LLC raised its stake in shares of Stryker by 3.6% in the 4th quarter. Capital Planning LLC now owns 841 shares of the medical technology company’s stock worth $304,000 after buying an additional 29 shares in the last quarter. Alhambra Investment Management LLC grew its holdings in Stryker by 1.5% during the fourth quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock worth $719,000 after acquiring an additional 29 shares during the period. Avestar Capital LLC raised its position in Stryker by 1.1% in the third quarter. Avestar Capital LLC now owns 2,948 shares of the medical technology company’s stock worth $1,065,000 after acquiring an additional 31 shares in the last quarter. Union Savings Bank lifted its holdings in Stryker by 1.0% in the 4th quarter. Union Savings Bank now owns 3,162 shares of the medical technology company’s stock valued at $1,138,000 after acquiring an additional 31 shares during the last quarter. Finally, Patrick M Sweeney & Associates Inc. boosted its position in shares of Stryker by 1.5% during the 3rd quarter. Patrick M Sweeney & Associates Inc. now owns 2,194 shares of the medical technology company’s stock valued at $793,000 after purchasing an additional 32 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on SYK. Truist Financial boosted their price target on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a report on Thursday. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. JPMorgan Chase & Co. raised their price objective on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research report on Wednesday. Barclays upped their target price on Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. Finally, Robert W. Baird raised their price target on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus price target of $419.37.

Insider Buying and Selling

In other news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.90% of the company’s stock.

Stryker Stock Up 0.1 %

Shares of SYK opened at $390.90 on Friday. The company has a 50-day simple moving average of $376.56 and a 200-day simple moving average of $362.38. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The firm has a market capitalization of $149.02 billion, a P/E ratio of 50.37, a P/E/G ratio of 2.68 and a beta of 0.95. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.86% and a net margin of 13.25%. During the same quarter in the previous year, the firm earned $3.46 EPS. On average, equities research analysts expect that Stryker Co. will post 13.53 earnings per share for the current year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st were given a dividend of $0.84 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend was Tuesday, December 31st. Stryker’s payout ratio is 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.